Copyright Notice
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Bookshelf ID: NBK500857PMID: 29999916
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 755037-03-7
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the clinical use of regorafenib during breastfeeding. Because regorafenib is 99.5% bound to plasma proteins, the amount in milk is likely to be low. However, one of its metabolites has a half-life of up to 70 hours, and might accumulate in the infant. The manufacturer recommends that breastfeeding be discontinued during regorafenib therapy and for 2 weeks after the final dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Regorafenib
CAS Registry Number
755037-03-7
Drug Class
- Breast Feeding
- Antineoplastic Agents
- Enzyme Inhibitors
- Protein Kinase Inhibitors
- Signal Transduction Inhibitors
- Tyrosine Kinase Inhibitors
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- Review Cabozantinib.[Drugs and Lactation Database (...]Review Cabozantinib.. Drugs and Lactation Database (LactMed®). 2006
- Review Gefitinib.[Drugs and Lactation Database (...]Review Gefitinib.. Drugs and Lactation Database (LactMed®). 2006
- Review Nintedanib.[Drugs and Lactation Database (...]Review Nintedanib.. Drugs and Lactation Database (LactMed®). 2006
- Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.[Cochrane Database Syst Rev. 2007]Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.Volmink J, Siegfried NL, van der Merwe L, Brocklehurst P. Cochrane Database Syst Rev. 2007 Jan 24; (1):CD003510. Epub 2007 Jan 24.
- Sucrose analgesia for heel-lance procedures in neonates.[Cochrane Database Syst Rev. 2023]Sucrose analgesia for heel-lance procedures in neonates.Yamada J, Bueno M, Santos L, Haliburton S, Campbell-Yeo M, Stevens B. Cochrane Database Syst Rev. 2023 Aug 30; 8(8):CD014806. Epub 2023 Aug 30.
- Regorafenib - Drugs and Lactation Database (LactMed®)Regorafenib - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...